pembrolizumab

Details

Key Milestones2
Call for patient/clinician input openFebruary 10, 2025
Call for patient/clinician input closedApril 07, 2025
Submission receivedMarch 25, 2025
Submission acceptedApril 08, 2025
Review initiatedApril 09, 2025
Draft CADTH review report(s) provided to sponsor for commentJune 27, 2025
Deadline for sponsors commentsJuly 09, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorJuly 31, 2025
Expert committee meeting (initial)August 13, 2025
Draft recommendation issued to sponsorAugust 25, 2025
To
August 27, 2025
Draft recommendation posted for stakeholder feedbackSeptember 04, 2025
End of feedback periodSeptember 18, 2025

pegunigalsidase alfa

Details

Key Milestones2
Call for patient/clinician input open06-Feb-25
Call for patient/clinician input closed31-Mar-25
Submission received04-Apr-25
Submission accepted22-Apr-25
Review initiated23-Apr-25
Draft CADTH review report(s) provided to sponsor for comment08-Jul-25
Deadline for sponsors comments17-Jul-25
CDA-AMC review report(s) and responses to comments provided to sponsor15-Aug-25
Expert committee meeting (initial)27-Aug-25
Draft recommendation issued to sponsor-
Draft recommendation posted for stakeholder feedback-
End of feedback period-

risperidone

Details

Key Milestones2
Call for patient/clinician input openFebruary 06, 2025
Call for patient/clinician input closedMarch 31, 2025
Submission receivedMarch 21, 2025
Submission acceptedApril 04, 2025
Review initiatedApril 07, 2025
Draft CADTH review report(s) provided to sponsor for commentJune 30, 2025
Deadline for sponsors commentsJuly 10, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorAugust 15, 2025
Expert committee meeting (initial)August 27, 2025
Draft recommendation issued to sponsorSeptember 09, 2025
To
September 11, 2025
Draft recommendation posted for stakeholder feedbackSeptember 18, 2025
End of feedback periodOctober 03, 2025

guselkumab

Details

Key Milestones2
Call for patient/clinician input openDecember 13, 2024
Call for patient/clinician input closedFebruary 18, 2025
Submission receivedJanuary 31, 2025
Submission acceptedFebruary 14, 2025
Review initiatedFebruary 18, 2025
Draft CADTH review report(s) provided to sponsor for commentMay 12, 2025
Deadline for sponsors commentsMay 22, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorJune 13, 2025
Expert committee meeting (initial)June 25, 2025
Draft recommendation issued to sponsorJuly 16, 2025
Draft recommendation posted for stakeholder feedbackJuly 24, 2025
End of feedback periodAugust 08, 2025

pembrolizumab

Details

Key Milestones2
Call for patient/clinician input openJanuary 31, 2025
Call for patient/clinician input closedMarch 31, 2025
Submission receivedMarch 18, 2025
Submission acceptedApril 01, 2025
Review initiatedApril 02, 2025
Draft CADTH review report(s) provided to sponsor for commentJune 18, 2025
Deadline for sponsors commentsJune 27, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorJuly 31, 2025
Expert committee meeting (initial)August 13, 2025
Draft recommendation issued to sponsorAugust 25, 2025
To
August 27, 2025
Draft recommendation posted for stakeholder feedbackSeptember 04, 2025
End of feedback periodSeptember 18, 2025

asciminib

Details

Key Milestones2
Call for patient/clinician input openJanuary 30, 2025
Call for patient/clinician input closedMarch 24, 2025
Submission receivedMarch 10, 2025
Submission acceptedMarch 25, 2025
Review initiatedMarch 26, 2025
Draft CADTH review report(s) provided to sponsor for commentJune 25, 2025
Deadline for sponsors commentsJuly 07, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorJuly 31, 2025
Expert committee meeting (initial)August 13, 2025
Draft recommendation issued to sponsorAugust 25, 2025
To
August 27, 2025
Draft recommendation posted for stakeholder feedbackSeptember 04, 2025
End of feedback periodSeptember 18, 2025

glofitamab

Details

Key Milestones2
Call for patient/clinician input openJanuary 29, 2025
Call for patient/clinician input closedMarch 24, 2025
Submission receivedMarch 07, 2025
Submission acceptedMarch 24, 2025
Review initiatedMarch 25, 2025
Draft CADTH review report(s) provided to sponsor for commentJune 27, 2025
Deadline for sponsors commentsJuly 09, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorJuly 31, 2025
Expert committee meeting (initial)August 13, 2025
Draft recommendation issued to sponsorAugust 25, 2025
To
August 27, 2025
Draft recommendation posted for stakeholder feedbackSeptember 04, 2025
End of feedback periodSeptember 18, 2025

Non-small Cell Lung Cancer

Details

Review Type: Rapid

As per requests from jurisdictions, this project will be combined with PH0065 to be delivered together in order to streamline the process and work. Please refer to the project timelines for PH0065 .